NASDAQ:VVUS - Vivus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.7867 -0.01 (-1.26 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$0.7867
Today's Range$0.7501 - $0.9050
52-Week Range$0.33 - $1.38
Volume5.34 million shs
Average Volume951,982 shs
Market Capitalization$84.84 million
P/E Ratio-2.71
Dividend YieldN/A
Beta0.56

About Vivus (NASDAQ:VVUS)

Vivus logoVIVUS, Inc., a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also involved in developing Qsymia, which has been completed Phase II studies for the treatment of various diseases, including obstructive sleep apnea and diabetes, nonalcoholic steatohepatitis and fatty liver disease, hyperlipidemia, and hypertension, as well as Tacrolimus that has been completed Phase IIa studies for the treatment of pulmonary arterial hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin Chemie AG to commercialize and promote STENDRA. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:VVUS
CUSIP92855110
Phone650-934-5200

Debt

Debt-to-Equity Ratio-12.06
Current Ratio8.67
Quick Ratio7.94

Price-To-Earnings

Trailing P/E Ratio-2.71
Forward P/E Ratio-1.83
P/E GrowthN/A

Sales & Book Value

Annual Sales$65.37 million
Price / Sales1.28
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-8.74

Profitability

EPS (Most Recent Fiscal Year)($0.29)
Net Income$-30,510,000.00
Net Margins-79.80%
Return on Equity-843.43%
Return on Assets-15.08%

Miscellaneous

Employees52
Outstanding Shares106,050,000

Vivus (NASDAQ:VVUS) Frequently Asked Questions

What is Vivus' stock symbol?

Vivus trades on the NASDAQ under the ticker symbol "VVUS."

How were Vivus' earnings last quarter?

Vivus (NASDAQ:VVUS) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.01. The biopharmaceutical company had revenue of $11.90 million for the quarter. Vivus had a negative return on equity of 843.43% and a negative net margin of 79.80%. View Vivus' Earnings History.

When is Vivus' next earnings date?

Vivus is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Vivus.

Who are some of Vivus' key competitors?

Who are Vivus' key executives?

Vivus' management team includes the folowing people:
  • Mr. Mark K. Oki, CFO & Chief Accounting Officer (Age 49)
  • Mr. John L. Slebir Esq., Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 53)
  • Dr. Santosh T. Varghese M.D., Chief Medical Officer (Age 48)
  • Mr. Seth H. Z. Fischer, Strategic Adviser (Age 62)
  • Mr. Thomas B. King, Interim CEO & Director (Age 63)

Has Vivus been receiving favorable news coverage?

Media stories about VVUS stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vivus earned a coverage optimism score of 0.01 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 44.49 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Vivus?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vivus' stock price today?

One share of VVUS stock can currently be purchased for approximately $0.7867.

How big of a company is Vivus?

Vivus has a market capitalization of $84.84 million and generates $65.37 million in revenue each year. The biopharmaceutical company earns $-30,510,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Vivus employs 52 workers across the globe.

How can I contact Vivus?

Vivus' mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]


MarketBeat Community Rating for Vivus (VVUS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  308 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Vivus and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vivus (NASDAQ:VVUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Vivus (NASDAQ:VVUS) Consensus Price Target History

Price Target History for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ:VVUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Vivus (NASDAQ:VVUS) Earnings History and Estimates Chart

Earnings by Quarter for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ:VVUS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.43 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Vivus (NASDAQ VVUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.11)N/AView Earnings Details
5/8/2018Q1 2018($0.11)($0.10)$11.90 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.13)($0.0950)$11.94 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.13)($0.0570)$16.00 million$15.19 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.13)$11.23 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.27)($0.22)ViewN/AView Earnings Details
8/2/2010Q2 2010($0.23)($0.28)ViewN/AView Earnings Details
5/3/2010Q1 2010($0.26)($0.23)ViewN/AView Earnings Details
3/8/2010Q4 2009($0.25)($0.16)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.31)($0.30)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.18)($0.19)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.08)($0.10)ViewN/AView Earnings Details
3/9/2009Q4 2008($0.05)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.05)$0.06ViewN/AView Earnings Details
5/8/2008Q1 2008$0.08($0.12)ViewN/AView Earnings Details
3/6/2008Q4 2007$0.21$0.17ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vivus (NASDAQ:VVUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vivus (NASDAQ VVUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 21.15%
Insider Trading History for Vivus (NASDAQ:VVUS)
Institutional Ownership by Quarter for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ VVUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018John P AmosCEOBuy540,000$0.56$302,400.00810,000View SEC Filing  
5/14/2018John P AmosCEOBuy540,000$0.52$280,800.00270,000View SEC Filing  
5/11/2018John P AmosCEOBuy270,000$0.52$140,400.00270,000View SEC Filing  
4/3/2018Santosh T VargheseInsiderSell390$0.34$132.60View SEC Filing  
1/31/2018Santosh T VargheseInsiderSell491$0.43$211.1371,805View SEC Filing  
1/1/2018Santosh T VargheseInsiderSell444$0.51$226.4472,296View SEC Filing  
10/3/2017Santosh T VargheseInsiderSell434$0.97$420.98View SEC Filing  
7/3/2017Santosh T VargheseInsiderSell423$1.23$520.2973,174View SEC Filing  
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.2073,597View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.1974,037View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.8074,830View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.4088,610View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.1388,966View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86101,525View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85101,891View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.9244,555View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.603,080View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vivus (NASDAQ VVUS) News Headlines

Source:
DateHeadline
-$0.11 Earnings Per Share Expected for Vivus (VVUS) This Quarter-$0.11 Earnings Per Share Expected for Vivus (VVUS) This Quarter
www.americanbankingnews.com - May 21 at 3:12 PM
BRIEF-Vivus Says Got Letter From Nasdaq Informing that it Granted Cos Request For Continued Listing, On ConditionsBRIEF-Vivus Says Got Letter From Nasdaq Informing that it Granted Co's Request For Continued Listing, On Conditions
www.reuters.com - May 18 at 11:01 AM
VIVUS (VVUS) Adds to Gains as CEO Buys Over 1M SharesVIVUS (VVUS) Adds to Gains as CEO Buys Over 1M Shares
www.streetinsider.com - May 18 at 11:01 AM
Insider Buying: Vivus (VVUS) CEO Purchases 540,000 Shares of StockInsider Buying: Vivus (VVUS) CEO Purchases 540,000 Shares of Stock
www.americanbankingnews.com - May 17 at 8:15 PM
Zacks Investment Research Upgrades Vivus (VVUS) to "Buy"Zacks Investment Research Upgrades Vivus (VVUS) to "Buy"
www.americanbankingnews.com - May 16 at 1:35 PM
Form 4 VIVUS INC For: May 11 Filed by: Amos John P.Form 4 VIVUS INC For: May 11 Filed by: Amos John P.
www.streetinsider.com - May 16 at 10:23 AM
Vivus (VVUS) CEO John P. Amos Buys 540,000 SharesVivus (VVUS) CEO John P. Amos Buys 540,000 Shares
www.americanbankingnews.com - May 15 at 10:10 PM
Insider Buying: Vivus (VVUS) CEO Buys 270,000 Shares of StockInsider Buying: Vivus (VVUS) CEO Buys 270,000 Shares of Stock
www.americanbankingnews.com - May 15 at 10:10 PM
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia FaltersVIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
www.zacks.com - May 10 at 9:56 AM
Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:56 AM
Vivus (VVUS) Issues  Earnings Results, Beats Estimates By $0.01 EPSVivus (VVUS) Issues Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 9 at 1:58 PM
Vivus (VVUS) CEO John Amos on Q1 2018 Results - Earnings Call TranscriptVivus' (VVUS) CEO John Amos on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:44 AM
Vivus: 1Q Earnings SnapshotVivus: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:44 AM
Vivus beats by $0.01, misses on revenueVivus beats by $0.01, misses on revenue
seekingalpha.com - May 8 at 4:19 PM
VIVUS Reports First Quarter 2018 Financial ResultsVIVUS Reports First Quarter 2018 Financial Results
www.globenewswire.com - May 8 at 4:16 PM
VIVUS Reports First Quarter 2018 Financial ResultsVIVUS Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:16 PM
VIVUS Announces Date of 2018 Annual MeetingVIVUS Announces Date of 2018 Annual Meeting
finance.yahoo.com - May 4 at 4:18 PM
Vivus (VVUS) Expected to Post Earnings of -$0.11 Per ShareVivus (VVUS) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - May 4 at 11:04 AM
Form 4 VIVUS INC For: Apr 30 Filed by: Oki Mark KForm 4 VIVUS INC For: Apr 30 Filed by: Oki Mark K
www.streetinsider.com - May 3 at 9:38 AM
VIVUS, Inc., New Team, New Acquisition Agreement, New Product, Analysts ReviewVIVUS, Inc., New Team, New Acquisition Agreement, New Product, Analysts Review
finance.yahoo.com - May 3 at 9:38 AM
Vivus (VVUS) Stock Rating Upgraded by ValuEngineVivus (VVUS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 2:02 PM
Today’s Research Reports on Stocks to Watch: Avinger and VIVUSToday’s Research Reports on Stocks to Watch: Avinger and VIVUS
finance.yahoo.com - May 2 at 9:39 AM
VIVUS (VVUS) Names John Amos as CEOVIVUS (VVUS) Names John Amos as CEO
www.streetinsider.com - May 1 at 9:41 AM
BRIEF-Vivus Expands Its Commercial Product Portfolio With The Acquisition Of PancreazeBRIEF-Vivus Expands Its Commercial Product Portfolio With The Acquisition Of Pancreaze
www.reuters.com - May 1 at 9:41 AM
BRIEF-Vivus Restructures Debt And Gains Access To New CapitalBRIEF-Vivus Restructures Debt And Gains Access To New Capital
www.reuters.com - May 1 at 9:41 AM
VIVUS (VVUS) Reports Acquisition of PANCREAZEVIVUS (VVUS) Reports Acquisition of PANCREAZE
www.streetinsider.com - May 1 at 9:41 AM
VIVUS Restructures Debt and Gains Access to New CapitalVIVUS Restructures Debt and Gains Access to New Capital
finance.yahoo.com - May 1 at 9:41 AM
VIVUS Strengthens Executive Leadership TeamVIVUS Strengthens Executive Leadership Team
finance.yahoo.com - May 1 at 9:41 AM
VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®
finance.yahoo.com - May 1 at 9:41 AM
Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
finance.yahoo.com - April 26 at 4:14 PM
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018
finance.yahoo.com - April 25 at 4:13 PM
Vivus (VVUS) to Release Quarterly Earnings on TuesdayVivus (VVUS) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:24 AM
Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?
finance.yahoo.com - April 12 at 10:39 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and ...Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and ...
www.prnewswire.com - April 10 at 4:13 PM
Vivus (VVUS) Lowered to Strong Sell at ValuEngineVivus (VVUS) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 2 at 10:23 PM
Zacks: Brokerages Anticipate VIVUS, Inc. (VVUS) to Announce -$0.11 Earnings Per ShareZacks: Brokerages Anticipate VIVUS, Inc. (VVUS) to Announce -$0.11 Earnings Per Share
www.americanbankingnews.com - March 31 at 8:32 AM
Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena FailedNovo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed
seekingalpha.com - March 24 at 4:36 PM
BRIEF-Vivus Reports Qtrly ‍loss Per Share $0.10BRIEF-Vivus Reports Qtrly ‍loss Per Share $0.10
www.reuters.com - March 14 at 12:37 PM
VIVUS (VVUS) Issues  Earnings ResultsVIVUS (VVUS) Issues Earnings Results
www.americanbankingnews.com - March 14 at 12:20 PM
VIVUS Reports Fourth Quarter 2017 Financial ResultsVIVUS Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 13 at 4:28 PM
Vivus reports 4Q lossVivus reports 4Q loss
finance.yahoo.com - March 13 at 4:28 PM
VIVUS (VVUS) Scheduled to Post Quarterly Earnings on TuesdayVIVUS (VVUS) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM
 Brokerages Expect VIVUS, Inc. (VVUS) to Announce -$0.13 EPS Brokerages Expect VIVUS, Inc. (VVUS) to Announce -$0.13 EPS
www.americanbankingnews.com - February 25 at 5:20 AM
Kadmon (KDMN) and VIVUS (VVUS) Critical AnalysisKadmon (KDMN) and VIVUS (VVUS) Critical Analysis
www.americanbankingnews.com - February 20 at 4:31 PM
Head to Head Survey: Transition Therapeutics (TTHI) and VIVUS (VVUS)Head to Head Survey: Transition Therapeutics (TTHI) and VIVUS (VVUS)
www.americanbankingnews.com - February 10 at 7:14 PM
VIVUS (VVUS) Raised to Sell at ValuEngineVIVUS (VVUS) Raised to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 12:38 PM
Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPSZacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPS
www.americanbankingnews.com - January 22 at 11:30 AM
Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUSFree Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS
www.bizjournals.com - January 17 at 10:30 AM
VIVUS (VVUS) Rating Lowered to Hold at Zacks Investment ResearchVIVUS (VVUS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 6 at 1:16 PM
-$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter-$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter
www.americanbankingnews.com - January 5 at 11:36 AM

SEC Filings

Vivus (NASDAQ:VVUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vivus (NASDAQ:VVUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vivus (NASDAQ VVUS) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.